|
| Title: description | Phase | Primary outcomes measure | Trial duration | ClinicalTrials.gov ID |
|
| Minocycline Therapy for Lung Scarring in Pts with IPF—A Pilot Study: evaluates the safety and efficacy of minocycline | 3 | Safety; efficacy | 9/13/2005 to (date n/a) | NCT00203697 |
|
| Interferon-Alpha Treatment of Chronic Cough in COPD and IPF: evaluates the effect lozenges containing interferon-alpha have on coughing | 2 | Frequency/severity of cough | 6/30/2008 to 3/31/2012 | NCT00690885 |
|
| Efficacy and Safety of Oral Bosentan in Pts with IPF: this double-blind, multicenter trial investigated the possible use of bosentan in pts with IPF | 2/3 | Change in 6MWD | 8/31/2003 to 5/31/2010 | NCT00071461 |
|
| Zileuton for the Treatment of IPF: an open-label trial of zileuton compared to azathioprine/prednisone for pts with IPF. Pts underwent a detailed assessment at baseline, followed by 3 mos of posttreatment monitoring for changes in symptoms and physiology | 2 | Change in LTB4 levels in bronchoalveolar lavage fluid | 1/31/2001 to (date n/a) | NCT00262405 |
|
| Open-Label, Extension Study in Patients with IPF Who Completed Protocol AC-052-321/BUILD 3: an open-label, extension study | 3 | Long-term safety and tolerability of bosentan | 3/31/2008 to 7/31/2010 | NCT00631475 |
|
| Bosentan Use in ILD: BUILD 3 was a prospective, multicenter, randomized, double-blind, parallel-group, placebo-controlled, event-driven, group sequential, superiority study | 3 | Time to occurrence of disease worsening or death up to end of study | 11/30/2006 to 7/31/2010 | NCT00391443 |
|
| Pirfenidone for the Treatment of Pts with PF/IPF: assessed the long-term safety and efficacy of oral pirfenidone in doses of up to 40 mg/kg/day | 2 | AEs, clinical laboratory tests, directed physical exams | 8/31/2003 to 1/31/2011 | NCT00080223 |
|
| Open-Label Study of the Long Term Safety of Pirfenidone in Pts with IPF: an open-label, multicenter, extension study for pts who completed the CAPACITY trials (PIPF-004 and PIPF-006) | 3 | Obtain safety data | 8/31/2008 to 7/31/2012 | NCT00662038 |
|
| Macitentan Use in an IPF Clinical Study: the AC-055B201/MUSIC study compared one dose of macitentan versus placebo in pts with IPF | 2 | FVC changes | 5/31/2009 to 6/30/2011 | NCT00903331 |
|
| Anticoagulant Effectiveness in IPF: tested the effectiveness of warfarin in pts with IPF | 3 | Time to death, nonbleeding/nonelective hospitalization, or >10% drop in FVC | 10/31/2009 to 12/31/2011 | NCT00957242 |
|
| Roll Over Study from 1199.30 BIBF-1120 in IPF: this open-label, non-randomized uncontrolled design trial offers continuation of BIBF-1120 treatment for pts with IPF who have completed a prior clinical trial (1199.30) with that drug. Primary objective is to establish a long-term tolerability and safety profile. Secondary objectives are effects of long-term treatment on survival, safety, and efficacy | 2 | FVC decline (time frame: 3 years average) | 6/30/2010 to 6/30/2015 | NCT01170065 |
|
